Achieve Life Sciences Inc. ACHV shares are up during Thursday's premarket session. Year to date, the stock has fallen around ...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2025 Earnings Call Transcript March 24, 2026 Achieve Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.43.

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...

Earnings call Achieve Life Sciences reported a pivotal Q3 2025, highlighted by FDA acceptance of its NDA for cytisinicline in smoking cessation with a PDUFA date of June 20, 2026. The company also ...

Achieve also AnnouncesPartnership with U.S.-based Adare Pharma Solutions for Cytisinicline ManufacturingConference Call ...

ACHV is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of ACHV shares has increased $0.12 since the market last closed. This is a 4.14% ...

SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...

Greetings, and welcome to the Achieve Life Sciences Third Quarter 2025 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. I would now like ...

Achieve Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.36981, expectations were $-0.37. Operator: Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings ...